18-Mar-2024
No headlines found.
Globe Newswire (Mon, 11-Mar 7:00 AM ET)
ADMA Biologics to Participate in the Raymond James Institutional Investor Conference
Globe Newswire (Tue, 5-Mar 7:00 AM ET)
ADMA Biologics Announces CFO Transition
Globe Newswire (Wed, 28-Feb 4:10 PM ET)
Globe Newswire (Wed, 28-Feb 4:05 PM ET)
ADMA Biologics to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
Globe Newswire (Wed, 21-Feb 4:05 PM ET)
ADMA Biologics Successfully Implements Innovative AI Program, Named ADMAlytics
Globe Newswire (Wed, 21-Feb 7:00 AM ET)
ADMA Biologics Announces Preliminary Fourth Quarter 2023 Revenue and Provides Business Update
Globe Newswire (Mon, 8-Jan 7:00 AM ET)
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
Adma Biologics trades on the NASDAQ stock market under the symbol ADMA.
As of March 18, 2024, ADMA stock price declined to $5.94 with 2,225,055 million shares trading.
ADMA has a beta of 0.90, meaning it tends to be less sensitive to market movements. ADMA has a correlation of 0.06 to the broad based SPY ETF.
ADMA has a market cap of $1.34 billion. This is considered a Small Cap stock.
Last quarter Adma Biologics reported $74 million in Revenue and $.04 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.02.
In the last 3 years, ADMA stock traded as high as $6.42 and as low as $1.01.
The top ETF exchange traded funds that ADMA belongs to (by Net Assets): VTI, XBI, IWM, VXF, IBB.
ADMA has outperformed the market in the last year with a price return of +91.6% while the SPY ETF gained +33.2%. ADMA has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +43.5% and +3.8%, respectively, while the SPY returned +9.0% and +0.4%, respectively.
ADMA support price is $5.85 and resistance is $6.13 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ADMA stock will trade within this expected range on the day.